Premium
RESPONSE TO NIVOLUMAB AS ≥3 rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS
Author(s) -
Lepik K.,
Mikhaylova N.,
Kondakova E.,
Tsvetkova L.,
Zalyalov Y.,
Borzenkova E.,
Moiseev I.,
Baykov V.,
Nikitina T.,
Porfir'eva N.,
Ionova T.,
Afanasyev B.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.174_2631
Subject(s) - medicine , nivolumab , quality of life (healthcare) , refractory (planetary science) , stage (stratigraphy) , oncology , gastroenterology , surgery , immunotherapy , cancer , paleontology , physics , nursing , astrobiology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom